Jump to navigation
Enter the article’s url One of our curators will take care of it as soon as possible!
Subscribe to our weekly newsletter.
In this piece, I will explain how the explanation of the emergence of life could also explain the mechanism of Deep Learning.
A US Research Integrity Advisory Board is long overdue. Such a leadership body would mitigate bad practices and strengthen good research.
London’s loss, as a result of Brexit vote, is lamented by U.K. researchers
Missing trial results undermine pandemic preparedness
The medicine, an antipsychotic drug, has a sensor that will show doctors whether and when patients are taking it. Other medicines will follow, experts say.
Huge genetic databases are changing how scientists study disease.
NIH Data Commons Pilot Phase to seek best practices for developing and managing a data commons.
Thomas Insel's biggest lesson from his shift from NIMH director to Silicon Valley entrepreneur: academic and technology company researchers should partner up.
More than 400 Pennsylvanians have already learned of disease mutations.
ADC Therapeutics, a Swiss start-up that specialises in cutting-edge cancer drugs, has raised almost CHF200 million ($200 million) in private funds.
Why Greek and Latin medical terminology is better off dead.
How Anne Wojcicki led her company from the brink of failure to scientific pre-eminence.
New law would allow commercial planting of transgenic varieties in Uganda.
A systematic review
Biologists are posting unreviewed manuscripts in record numbers. But many are still not sure it's a good idea. A survival guide for scientists.
Nowhere near enough new drugs are currently in development says a WHO report, which calls for urgent investment and responsible use of existing antibiotics.
Combining expertise from 21 labs in Europe and the US, the International Brain Laboratory will attempt to answer one of the greatest mysteries of all time.
Modelled on big physics projects, the International Brain Lab will bring together some of the world’s pre-eminent neuroscientists to probe a single behaviour.
Approval of Novartis cancer drug is “historic,” FDA says
A historian recounts the National Institutes of Health's 1960s pilot test of exchanging unreviewed manuscripts, and how publishers killed it.